TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07215702: A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants With Sepsis-associated Acute Kidney Injury (SERENIA)

Sponsor: AstraZeneca · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 124 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,617,000

Rescue Site Savings

+$1,058,400

Unlock Full NCT07215702 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07215702 Rescue Dossier →